Number of metabolic syndrome risk parameters associated with TAFIa/ai antigen levels

Basit Öğe Kaydı
dc.authoridAsik, mehmet/0000-0002-0716-0221
dc.authoridKizilgun, Murat/0000-0001-5551-4058
dc.contributor.authorGunes, Fahri
dc.contributor.authorAkbal, Erdem
dc.contributor.authorAsik, Mehmet
dc.contributor.authorSen, Hacer
dc.contributor.authorBinnetoglu, Emine
dc.contributor.authorKizilgun, Murat
dc.contributor.authorOzbek, Mustafa
dc.date.accessioned2025-01-27T20:11:50Z
dc.date.available2025-01-27T20:11:50Z
dc.date.issued2013
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThrombin activatable fibrinolysis inhibitor (TAFI) is an important procoagulant factor. Patients with metabolic syndrome (MetS) also have an elevated procoagulant status. However, TAFI and its association with MetS are still not well known. We aimed to investigate TAFI in type 2 diabetes mellitus patients with MetS. We enrolled a total of 55 patients who had MetS (n=30) and 25 healthy controls. MetS was diagnosed using National Cholesterol Education Program Adult Treatment Panel III criteria. We measured activated and inactivated TAFI (TAFIa/ai) antigen in plasma samples using a commercially available ELISA kit (Imubind TAFIa/ai antigen ELISA; American Diagnostica Inc., Stamford, Connecticut, USA). TAFIa/ai levels were then evaluated for links to MetS parameters. Mean TAFIa/ai levels were 156.6 +/- 66.9ng/dl in patients with MetS and 104.1 +/- 60.3ng/dl in the control group (P=0.005). None of the MetS parameters, including blood pressure, fasting plasma glucose, waist circumference, triglycerides or high-density lipoprotein cholesterol (HDL-C) levels were correlated with TAFIa/ai levels. However, TAFIa/ai level had a strong correlation with the number of metabolic risk components, which increased proportionally when MetS parameters were over three. When there were increased numbers of MetS risk components, we detected a rise in TAFIa/ai levels. TAFIa/ai levels could be an indicator of atherosclerotic tendency in patients with MetS. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
dc.identifier.doi10.1097/MBC.0b013e328364668a
dc.identifier.endpage847
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.issue8
dc.identifier.pmid23945058
dc.identifier.scopus2-s2.0-84888131110
dc.identifier.scopusqualityQ3
dc.identifier.startpage844
dc.identifier.urihttps://doi.org/10.1097/MBC.0b013e328364668a
dc.identifier.urihttps://hdl.handle.net/20.500.12428/20742
dc.identifier.volume24
dc.identifier.wosWOS:000326815600008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofBlood Coagulation & Fibrinolysis
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectmetabolic syndrome
dc.subjectcardiovascular risk
dc.subjectthrombin activatable fibrinolysis inhibitor
dc.titleNumber of metabolic syndrome risk parameters associated with TAFIa/ai antigen levels
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu